What the review covers The Post-Authorization Activity Table for Mounjaro indicates the review was started between November 1 and November 30, 2024 [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629]
Exosomes: If you are not responding as expected to BPC-157 or other peptides, we can add exosomes tiny, yet powerful, particles that play a crucial role in stem cell therapy by acting as messengers, delivering regenerative signals to cells throughout the body
Side-by-side compound comparison Receptor targets Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only Retatrutide GLP-1 + GIP + Glucagon (triple) Half-life Tirzepatide ~5 days Semaglutide ~7 days Retatrutide ~6 days Dosing frequency Tirzepatide Once weekly Semaglutide Once weekly Retatrutide Once weekly Max studied dose Tirzepatide 15 mg / week Semaglutide 2.4 mg / week (Wegovy) Retatrutide 12 mg / week Peak weight loss Tirzepatide 22.5% (SURMOUNT-1, 72 wk) Semaglutide 15.8% (STEP-1, 68 wk) Retatrutide 24.2% (Phase 2, 48 wk) FDA status (June 2026) Tirzepatide Approved (T2D, obesity, OSA) Semaglutide Approved (T2D, obesity, CV risk) Retatrutide Investigational Phase 3 Head-to-head Tirzepatide 20.2% vs semaglutide 13.7% (SURMOUNT-5) Semaglutide Retatrutide Not yet head-to-head vs tirzepatide HFpEF benefit Tirzepatide Yes (SUMMIT, HR 0.62) Semaglutide Yes (STEP-HFpEF) Retatrutide Not yet studied Unique advantage Tirzepatide Best-in-class FDA-approved efficacy
In April, WW (ne Weight Watchers) purchased Sequence, a telehealth subscription service that connects patients with doctors who can prescribe obesity and diabetes drugs
The new program aims to lower patients' cost uncertainty to help people stay on the FDA-approved GLP-1 obesity treatment
Working with a qualified coach or trainer who understands body composition changes the outcome significantly
